mAbsImmunologyPeer-reviewed journal article
Beyond Sequence Similarity: ML-Powered Identification of pHLA Off-Targets for TCR-Mimic Antibodies Using High Throughput Binding Kinetics
Alexander Sinclair, Stefan KrämeriD, Christoph ReinhartiD, Jennifer Stehle, Simon SchusteriD, Tobias HerziD, Hoor Al-HasaniiD, Pranav Hamde, Oliver SelingeriD, Jörg BirkenfeldiD
Abstract
T-cell receptor mimic (TCRm) antibodies are an emerging class of tumor-targeting agents used in advanced immunother-apies such as bispecific T-cell engagers and CAR-T cells. Unlike conventional antibodies, TCRms are designed to recognize peptide-human leukocyte antigen (pHLA) complexes that present intracellular tumor-derived peptides on the cell surface. Due to the typically low surface abundance and high sequence similarity of pHLAs, TCRms require high affinity and exceptional specificity to avoid off-target toxicity. Conventional methods for off-target identification such as sequence similarity searches, motif-based screening, and structural modelling focus on the peptide and are limited in detecting cross-reactive peptides with little or no sequence homology to the target. To address this gap, we developed EpiPredict, a TCRm-specific machine learning framework trained on high-throughput kinetic off-target screening data. EpiPredict learns an antibody-specific mapping from peptide sequence to binding strength, enabling prediction of interactions with unmeasured pHLA sequences, including sequence-dissimilar peptides. We applied EpiPredict to two distinct TCRms targeting the cancer-testis antigen MAGE-A4. The model successfully predicted multiple off-targets with minimal sequence similarity to the intended epitope, many of which were experimentally validated via T2 cell binding assays. These findings establish EpiPredict as a valuable tool for lead optimization of TCRms, enabling the identification of antibody-specific off-targets beyond the scope of traditional peptide-centric methods and supporting the preclinical de-risking of TCRm-based therapies.
- organism: human
- assay: proteomics
- research focus: drug response / drug discovery
- research focus: benchmarking
- approach: machine learning (classical)
- Citations
- 3
- FWCI
- 0.90
- Field percentile
- top 27%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- EpiTox: A Multi-Modular Framework for Population-Aware Off-Target Prediction Highlighting MAGE-A3 Cross-Reactivity
Hoor Al-Hasani, Mazhar Ali, … Simon Schuster·bioRxiv·Dec 12, 2025
- Systematic De-Risking of TCR-Mimic Therapeutics Through Proteome-Wide Off-Target Landscaping and a Generalizable Design Rule Framework
Simon Schuster, Frederike A. Hartl, … Jörg Birkenfeld·bioRxiv·Aug 4, 2026
- Computationally profiling peptide:MHC recognition by T-cell receptors and T-cell receptor-mimetic antibodies
M. I. J. Raybould, D. A. Nissley, … C. M. Deane·bioRxiv·Jul 15, 2022
- De novo design and structure of a peptide-centric TCR mimic binding module
Karsten D. Householder, Xinyu Xiang, … K. Christopher García·SciencePeer-reviewed·Jul 24, 2025
- A structure-guided approach to predict MHC-I restriction of T cell receptors for public antigens
S. K. Gupta, Nikolaos G. Sgourakis·StructurePeer-reviewed·Jun 6, 2024
- Predicting specificity of TCR-pMHC interactions using machine learning and biophysical models
Martin Culka, Nicolas Lounsbury, … Mohammed AlQuraishi·Cell SystemsPeer-reviewed·Aug 13, 2026